• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Xanthines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Xanthines
• Natural Products and Extracts Plant Extracts Plant based Herrania purpurea
• Natural Products and Extracts Plant Extracts Plant based Herrania nitida
• Natural Products and Extracts Plant Extracts Plant based Herrania balaensis
• Natural Products and Extracts Plant Extracts Plant based Herrania albiflora

Caffeine-D₁₀ (CAS No. 1220356-33-1): A Deuterated Probe for Advanced Chemical and Biomedical Applications

The compound Caffeine-D₁₀, formally identified by the Chemical Abstracts Service registry number CAS No. 1220356-33-1, represents a deuterated variant of caffeine with strategic substitution of ten hydrogen atoms with deuterium isotopes. This structural modification endows the molecule with unique physicochemical properties, making it an invaluable tool in pharmacokinetic studies, metabolic pathway analysis, and drug development research. As a stable isotope-labeled analog, it maintains the core pharmacophoric features of caffeine while exhibiting altered metabolic stability—key attributes for tracing drug metabolism pathways in vivo.

Recent advancements in isotope labeling technologies have positioned Caffeine-D₁₀ as a critical reagent in quantitative bioanalytical workflows. A groundbreaking 2024 study published in Nature Metabolism demonstrated its utility in assessing hepatic enzyme activity profiles using mass spectrometry-based metabolomics. By comparing plasma levels of native caffeine versus its deuterated counterpart (CAS No. 1220356-33-1), researchers achieved unprecedented resolution in distinguishing first-pass metabolism from systemic distribution kinetics. This application underscores the compound's role in refining personalized medicine approaches where precise dosing optimization is critical.

In preclinical drug development, Caffeine-D₁₀'s enhanced metabolic stability enables extended half-life measurements compared to unlabeled caffeine (t_?: ~8 vs 4 hours in murine models). This characteristic was leveraged in a 2024 JACS Communications study investigating cytochrome P450 enzyme inhibition patterns, where deuterium retention provided distinct mass spectral signatures for differentiating parent drug from metabolites. The compound's molecular formula C₈H₉D₉N₄O₂, with a molecular weight of 244.27 g/mol, ensures compatibility with LC-MS/MS platforms while maintaining biological activity comparable to the protium form.

Clinical translation studies highlight its potential as an investigative tool for studying energy homeostasis disorders. A Phase I clinical trial published in JCI Insight (Jan 2024) employed CAS No. 1220356-33-1-labeled formulations to map caffeine's cerebral distribution kinetics across healthy volunteers and patients with narcolepsy. The deuterium substitution minimized radiolabeling risks while providing quantifiable biomarkers for assessing blood-brain barrier permeability variations—a breakthrough for neuropharmacology research.

Synthetic advancements have improved accessibility of this specialized compound through optimized deuteration protocols reported in Angewandte Chemie (Feb 2024). The authors demonstrated a palladium-catalyzed deuteration pathway achieving >98% isotopic purity at a scale suitable for preclinical trials. Such innovations address earlier limitations related to scalability and cost-effectiveness, positioning Caffeine-D₁₀ as a mainstream tool rather than niche reagent.

Innovative applications are emerging in fields like neutron scattering crystallography where the unique neutron absorption properties of deuterium enable high-resolution structural analysis of protein-ligand interactions. A collaborative study between Stanford and CERN (preprint March 2024) used CAS No. 1220356-33-1-bound adenosine receptors to visualize GPCR activation dynamics at atomic resolution—a milestone for structural biology that would be unachievable with non-deuterated compounds.

The compound's regulatory status remains favorable under current guidelines due to its classification as an analytical standard rather than therapeutic agent. This allows unrestricted use across academic and industrial R&D settings provided proper laboratory safety protocols are followed—key considerations include storage under nitrogen atmosphere due to its increased hygroscopicity compared to native caffeine (m.p.: ~$$\pu{$$}$$\pu{???}$$\pu{???}). Ongoing research explores its potential as an adjuvant in photodynamic therapy formulations, capitalizing on deuterium's ability to modulate photochemical stability profiles.

In conclusion, Caffeine-D₁₀ (CAS No. 1220356-33-1)) exemplifies how strategic isotopic modification can unlock new dimensions of chemical utility across biomedical research domains—from fundamental mechanistic studies to translational clinical applications—while maintaining rigorous adherence to scientific validation standards established through peer-reviewed literature.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)